Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of belactosin a: Synthesis, biological activity, and mode of action

Journal of Medicinal Chemistry

Volumn 56, Issue 9, 2013, Pages 3689-3700

  Kawamura, Shuhei ^a   Unno, Yuka ^b   List, Anja ^c   Mizuno, Akirai ^a   Tanaka, Motohiro ^d   Sasaki, Takuma ^d   Arisawa, Mitsuhiro ^a   Asai, Akira ^b   Groll, Michael ^c   Shuto, Satoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BELACTOSIN A; BORTEZOMIB; CARFILZOMIB; CHYMOTRYPSIN; CIS CYCLOPROPANE DERIVATIVE; CYCLOPROPANE DERIVATIVE; LACTACYSTIN; LACTACYSTIN BETA LACTONE; NATURAL PRODUCT; PR 957; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; COVALENT BOND; DRUG DESIGN; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SUBUNIT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; PROTEIN STABILITY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CELL PROLIFERATION; CHEMISTRY TECHNIQUES, SYNTHETIC; CRYSTALLOGRAPHY, X-RAY; CYCLOPROPANES; DRUG STABILITY; HCT116 CELLS; HUMANS; ISOMERISM; MODELS, MOLECULAR; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN CONFORMATION; WATER;

EID: 84877697520     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4002296     Document Type: Article

References (57)

1. Orlowski, M. The multicatalytic proteinase complex, a major extralysosomal proteolytic system Biochemistry 1990, 29, 10289-10297
2. Ciechanover, A. The ubiquitin-proteasome proteolytic pathway Cell 1994, 79, 13-21
3. Fuchs, S. Y. The role of ubiquitin-proteasome pathway in oncogenic signaling Cancer Biol. Ther. 2002, 1, 337-341
4. Chen, J. J.; Lin, F.; Qin, Z. H. The roles of the proteasome pathway in signal transduction and neurodegenerative diseases Neurosci. Bull. 2008, 24, 183-194
5. Muchamuel, T.; Basler, M.; Aujay, M. A.; Suzuki, E.; Kalim, K. W.; Lauer, C.; Sylvain, C.; Ring, E. R.; Shields, J.; Jiang, J.; Shwonek, P.; Parlati, F.; Demo, S. D.; Bennett, M. K.; Kirk, C. J.; Groettrup, M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis Nat. Med. 2009, 15, 781-787
6. King, R. W.; Deshaies, R. J.; Peters, J. M.; Kirschner, M. W. How proteolysis drives the cell cycle Science 1996, 274, 1652-1659
7. Huber, E. M.; Groll, M. Inhibitors for the Immuno-and Constitutive Proteasome: Current and Future Trends in Drug Development Angew. Chem., Int. Ed. 2012, 51, 8708-8720
8. Adams, J. The proteasome: a suitable antineoplastic target Nat. Rev. Cancer 2004, 4, 349-360
9. Bross, P. F.; Kane, R.; Farrell, A. T.; Abraham, S.; Benson, K.; Brower, M. E.; Bradley, S.; Gobburu, J. V.; Goheer, A.; Lee, S. L.; Leighton, J.; Liang, C. Y.; Lostritto, R. T.; McGuinn, W. D.; Morse, D. E.; Rahman, A.; Rosario, L. A.; Verbois, S. L.; Williams, G.; Wang, Y. C.; Pazdur, R. Approval summary for bortezomib for injection in the treatment of multiple myeloma Clin. Cancer Res. 2004, 10, 3954-3964
10. Kane, R. C.; Farrell, A. T.; Sridhara, R.; Pazdur, R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy Clin. Cancer Res. 2006, 12, 2955-2960
11. Kane, R. C.; Dagher, R.; Farrell, A.; Ko, C. W.; Sridhara, R.; Justice, R.; Pazdur, R. Bortezomib for the treatment of mantle cell lymphoma Clin. Cancer Res. 2007, 13, 5291-5294
12. Groll, M.; Ditzel, L.; Lowe, J.; Stock, D.; Bochtler, M.; Bartunik, H. D.; Huber, R. Structure of 20S proteasome from yeast at 2.4A resolution Nature 1997, 386, 463-471
13. Groll, M.; Clausen, T. Molecular shredders: how proteasomes fulfill their role Curr. Opin. Struct. Biol. 2003, 13, 665-673
14. Huber, E. M.; Basler, M.; Schwab, R.; Heinemeyer, W.; Kirk, C. J.; Groettrup, M.; Groll, M. Immuno-and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity Cell 2012, 148, 727-738
15. Murata, S.; Sasaki, K.; Kishimoto, T.; Niwa, S.-i.; Hayashi, H.; Takahama, Y.; Tanaka, K. Regulation of CD8+ T Cell Development by Thymus-Specific Proteasomes Science 2007, 316, 1349-1353
16. Parlati, F.; Lee, S. J.; Aujay, M.; Suzuki, E.; Levitsky, K.; Lorens, J. B.; Micklem, D. R.; Ruurs, P.; Sylvain, C.; Lu, Y.; Shenk, K. D.; Bennett, M. K. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome Blood 2009, 114, 3439-3447
17. Asai, A.; Hasegawa, A.; Ochiai, K.; Yamashita, Y.; Mizukami, T. Belactosin A, a novel antitumor antibiotic acting on cyclin/CDK mediated cell cycle regulation, produced by Streptomyces sp J. Antibiot. 2000, 53, 81-83
18. Asai, A.; Tsujita, T.; Sharma, S. V.; Yamashita, Y.; Akinaga, S.; Funakoshi, M.; Kobayashi, H.; Mizukami, T. A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay Biochem. Pharmacol. 2004, 67, 227-234
19. Groll, M.; Larionov, O. V.; Huber, R.; De Meijere, A. Inhibitor-binding mode of homobelactosin C to proteasomes: New insights into class I MHC ligand generation Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 4576-4579
20. Korotkov, V. S.; Ludwig, A.; Larionov, O. V.; Lygin, A. V.; Groll, M.; de Meijere, A. Synthesis and biological activity of optimized belactosin C congeners Org. Biomol. Chem. 2011, 9, 7791-7798
21. Borissenko, L.; Groll, M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development Chem. Rev. 2007, 107, 687-717
22. Groll, M.; Kim, K. B.; Kairies, N.; Huber, R.; Crews, C. M. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of α,β-epoxyketone proteasome inhibitors J. Am. Chem. Soc. 2000, 122, 1237-1238
23. Groll, M.; Berkers, C. R.; Ploegh, H. L.; Ovaa, H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome Structure 2006, 14, 451-456
24. Groll, M.; Huber, R.; Potts, B. C. M. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding J. Am. Chem. Soc. 2006, 128, 5136-5141
25. Groll, M.; Schellenberg, B.; Bachmann, A. S.; Archer, C. R.; Huber, R.; Powell, T. K.; Lindow, S.; Kaiser, M.; Dudler, R. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism Nature 2008, 452, 755-758
26. Hines, J.; Groll, M.; Fahnestock, M.; Crews, C. M. Proteasome inhibition by fellutamide B induces nerve growth factor synthesis Chem. Biol. 2008, 15, 501-512
27. Clerc, J.; Groll, M.; Illich, D. J.; Bachmann, A. S.; Huber, R.; Schellenberg, B.; Dudler, R.; Kaiser, M. Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 6507
28. Blackburn, C.; Barrett, C.; Blank, J. L.; Bruzzese, F. J.; Bump, N.; Dick, L. R.; Fleming, P.; Garcia, K.; Hales, P.; Hu, Z. Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome Bioorg. Med. Chem. Lett. 2010, 20, 6581-6586
29. Grawert, M. A.; Gallastegui, N.; Stein, M.; Schmidt, B.; Kloetzel, P. M.; Huber, R.; Groll, M. Elucidation of the alpha-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibition Angew. Chem., Int. Ed. 2011, 50, 542-544
30. Gallastegui, N.; Beck, P.; Arciniega, M.; Huber, R.; Hillebrand, S.; Groll, M. Hydroxyureas as Noncovalent Proteasome Inhibitors Angew. Chem., Int. Ed. 2012, 51, 247-249
31. Huber, E. M.; Basler, M.; Schwab, R.; Heinemeyer, W.; Kirk, C. J.; Groettrup, M.; Groll, M. Immuno-and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity Cell 2012, 148, 727-738
32. Armstrong, P. D.; Cannon, J. G.; Long, J. P. Conformationally Rigid Analogues of Acetylcholine Nature 1968, 220, 65-66
33. Kazuta, Y.; Hirano, K.; Natsume, K.; Yamada, S.; Kimura, R.; Matsumoto, S.; Furuichi, K.; Matsuda, A.; Shuto, S. Cyclopropane-based conformational restriction of histamine. (1 S,2 S)-2-(2-aminoethyl)-1-(1 H-imidazol-4-yl) cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure J. Med. Chem. 2003, 46, 1980-1988
34. Watanabe, M.; Kazuta, Y.; Hayashi, H.; Yamada, S.; Matsuda, A.; Shuto, S. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure J. Med. Chem. 2006, 49, 5587-5596
35. Watanabe, M.; Kobayashi, T.; Hirokawa, T.; Yoshida, A.; Ito, Y.; Yamada, S.; Orimoto, N.; Yamasaki, Y.; Arisawa, M.; Shuto, S. Cyclopropane-based stereochemical diversity-oriented conformational restriction strategy: histamine H3 and/or H4 receptor ligands with the 2,3-methanobutane backbone Org. Biomol. Chem. 2012, 10, 736-745
36. Yoshida, K.; Yamaguchi, K.; Sone, T.; Unno, Y.; Asai, A.; Yokosawa, H.; Matsuda, A.; Arisawa, M.; Shuto, S. Synthesis of 2,3-and 3,4-methanoamino acid equivalents with stereochemical diversity and their conversion into the tripeptide proteasome inhibitor belactosin A and its highly potent cis-cyclopropane stereoisomer Org. Lett. 2008, 10, 3571-3574
37. Adams, J.; Behnke, M.; Chen, S.; Cruickshank, A. A.; Dick, L. R.; Grenier, L.; Klunder, J. M.; Ma, Y. T.; Plamondon, L.; Stein, R. L. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids Bioorg. Med. Chem. Lett. 1998, 8, 333-338
38. Demo, S. D.; Kirk, C. J.; Aujay, M. A.; Buchholz, T. J.; Dajee, M.; Ho, M. N.; Jiang, J.; Laidig, G. J.; Lewis, E. R.; Parlati, F.; Shenk, K. D.; Smyth, M. S.; Sun, C. M.; Vallone, M. K.; Woo, T. M.; Molineaux, C. J.; Bennett, M. K. Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome Cancer Res. 2007, 67, 6383-6391
39. Kuhn, D. J.; Chen, Q.; Voorhees, P. M.; Strader, J. S.; Shenk, K. D.; Sun, C. M.; Demo, S. D.; Bennett, M. K.; van Leeuwen, F. W.; Chanan-Khan, A. A.; Orlowski, R. Z. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood 2007, 110, 3281-3290
40. Yoshida, K.; Yamaguchi, K.; Mizuno, A.; Unno, Y.; Asai, A.; Sone, T.; Yokosawa, H.; Matsuda, A.; Arisawa, M.; Shuto, S. Three-dimensional structure-activity relationship study of belactosin A and its stereo-and regioisomers: development of potent proteasome inhibitors by a stereochemical diversity-oriented strategy Org. Biomol. Chem. 2009, 7, 1868-1877
41. Kazuta, Y.; Matsuda, A.; Shuto, S. Development of Versatile cis-and trans-Dicarbon-Substituted Chiral Cyclopropane Units: Synthesis of (1 S,2 R)-and (1 R,2 R)-2-Aminomethyl-1-(1 H-imidazol-4-yl)cyclopropanes and Their Enantiomers as Conformationally Restricted Analogues of Histamine J. Org. Chem. 2002, 67, 1669-1677
42. Watanabe, M.; Hirokawa, T.; Kobayashi, T.; Yoshida, A.; Ito, Y.; Yamada, S.; Orimoto, N.; Yamasaki, Y.; Arisawa, M.; Shuto, S. Investigation of the bioactive conformation of histamine H3 receptor antagonists by the cyclopropylic strain-based conformational restriction strategy J. Med. Chem. 2010, 53, 3585-3593
43. Armstrong, A.; Scutt, J. N. Total synthesis of (+)-belactosin A Chem. Commun. 2004, 510-511
44. Charette, A. B.; Juteau, H. Design of Amphoteric Bifunctional Ligands-Application to the Enantioselective Simmons-Smith Cyclopropanation of Allylic Alcohols J. Am. Chem. Soc. 1994, 116, 2651-2652
45. Charette, A. B.; Juteau, H.; Lebel, H.; Molinaro, C. Enantioselective cyclopropanation of allylic alcohols with dioxaborolane ligands: Scope and synthetic applications J. Am. Chem. Soc. 1998, 120, 11943-11952
46. Arastu-Kapur, S.; Anderl, J. L.; Kraus, M.; Parlati, F.; Shenk, K. D.; Lee, S. J.; Muchamuel, T.; Bennett, M. K.; Driessen, C.; Ball, A. J.; Kirk, C. J. Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events Clin. Cancer Res. 2011, 17, 2734-2743
47. Muchamuel, T.; Basler, M.; Aujay, M. A.; Suzuki, E.; Kalim, K. W.; Lauer, C.; Sylvain, C.; Ring, E. R.; Shields, J.; Jiang, J.; Shwonek, P.; Parlati, F.; Demo, S. D.; Bennett, M. K.; Kirk, C. J.; Groettrup, M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis Nat. Med. 2009, 15, 781-787
48. Honda, R.; Tanaka, H.; Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 FEBS Lett. 1997, 420, 25-27
49. Levine, A. J. p53, the Cellular Gatekeeper for Growth and Division Cell 1997, 88, 323-331
50. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 network Nature 2000, 408, 307-310
51. Vousden, K. H.; Lu, X. Live or let die: the cell's response to p53 Nat. Rev. Cancer 2002, 2, 594-604
52. Oren, M. Decision making by p53: life, death and cancer Cell Death Differ. 2003, 10, 431-442
53. Duriez, P. J.; Shah, G. M. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death Biochem. Cell Biol. 1997, 75, 337-349
54. Kaufmann, S. H.; Desnoyers, S.; Ottaviano, Y.; Davidson, N. E.; Poirier, G. G. Specific Proteolytic Cleavage of Poly(ADP-ribose) Polymerase: An Early Marker of Chemotherapy-induced Apoptosis Cancer Res. 1993, 53, 3976-3985
55. Williamson, M. J.; Blank, J. L.; Bruzzese, F. J.; Cao, Y.; Daniels, J. S.; Dick, L. R.; Labutti, J.; Mazzola, A. M.; Patil, A. D.; Reimer, C. L.; Solomon, M. S.; Stirling, M.; Tian, Y.; Tsu, C. A.; Weatherhead, G. S.; Zhang, J. X.; Rolfe, M. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib Mol. Cancer Ther. 2006, 5, 3052-3061
56. Groll, M.; Huber, R.; Potts, B. C. M. Crystal Structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in Complex with the 20S Proteasome Reveal Important Consequences of β-Lactone Ring Opening and a Mechanism for Irreversible Binding J. Am. Chem. Soc. 2006, 128, 5136-5141
57. Kupperman, E.; Lee, E. C.; Cao, Y.; Bannerman, B.; Fitzgerald, M.; Berger, A.; Yu, J.; Yang, Y.; Hales, P.; Bruzzese, F.; Liu, J.; Blank, J.; Garcia, K.; Tsu, C.; Dick, L.; Fleming, P.; Yu, L.; Manfredi, M.; Rolfe, M.; Bolen, J. Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer Cancer Res. 2010, 70, 1970-1980